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OBJECTIVES: Fibrolamellar hepatocellular carcinoma is a rare primary malignant liver tumor that differs from
conventional hepatocellular carcinoma in several aspects. The aim of this study was to describe the clinical,
surgical and histopathological features of fibrolamellar hepatocellular carcinoma and to analyze the factors
associated with survival.
METHODS: We identified 21 patients with histopathologically diagnosed fibrolamellar hepatocellular
carcinoma over a 22-year period. Clinical information was collected from medical records and biopsies, and
surgical specimens were reviewed.
RESULTS: The median age at diagnosis was 20 years. Most patients were female (67%) and did not have
associated chronic liver disease. Most patients had a single nodule, and the median tumor size was 120 mm.
Vascular invasion was present in 31% of patients, and extra-hepatic metastases were present in 53%. Fourteen
patients underwent surgery as the first-line therapy, three received chemotherapy, and four received palliative
care. Eighteen patients had ‘‘pure fibrolamellar hepatocellular carcinoma,’’ whereas three had a distinct area of
conventional hepatocellular carcinoma and were classified as having ‘‘mixed fibrolamellar hepatocellular
carcinoma.’’ The median overall survival was 36 months. The presence of ‘‘mixed fibrolamellar hepatocellular
carcinoma’’ and macrovascular invasion were predictors of poor survival. Vascular invasion was associated with
an increased risk of recurrence in patients who underwent surgery.
CONCLUSION: Fibrolamellar hepatocellular carcinoma was more common in young female patients without
chronic liver disease. Surgery was the first therapeutic option to achieve disease control, even in advanced
cases. Vascular invasion was a risk factor for tumor recurrence. The presence of macrovascular invasion and
areas of conventional hepatocellular carcinoma were directly related to poor survival.
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Fibrolamellar hepatocellular carcinoma (FLHCC) was
first described by Edmondson in 1956 as ‘‘a rare, distinct
form of primary hepatocellular carcinoma’’ (1). It is
histologically characterized by large polygonal hepatocytes
with eosinophilic and granular cytoplasm surrounded by
abundant, thick fibrous bands, which are arranged in a
parallel or lamellar distribution (2,3). FLHCC represents 1 -
2% of all primary liver tumors, which is a small percentage
compared with that of conventional HCC, which represents
60-80% of liver cancers (4,5). To the best of our knowledge,
there are only four reports of FLHCC from Latin American
populations (6-8) and no previous reports from Brazil. The
actual incidence of FLHCC in Latin America remains
unknown.
FLHCC differs from conventional HCC in several aspects,
such as demographics, risk factors and tumor markers (4,5).
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FLHCC typically occurs in younger patients, with a median
age at diagnosis of 25 years old, and has a controversial
gender predilection (9-11). In contrast to conventional HCC,
the vast majority of cases occur in patients without chronic
liver disease or cirrhosis (4,9,12). Conventional tumor
markers for HCC, such as alpha-fetoprotein (AFP), are
normal in the majority of patients (4).
Controversy exists regarding whether FLHCC has a better
prognosis than conventional HCC. Several studies had
formerly described FLHCC as more indolent and associated
with a better prognosis (10,13-15), but subsequent studies
found that survival after resection was similar in patients
with FLHCC and conventional HCC without cirrhosis (16-
18). It is conceivable that a better outcome for FLHCC would
be derived from the absence of cirrhosis, high resectability
rates, and a younger age at presentation rather than from
the distinct biological and clinicopathological features of the
tumor itself (4,9,16). A recent multicenter French study has
suggested that the presence of some tumor heterogeneity,
with classical FLHCC intermingled with conventional HCC,
would be responsible for a worse prognosis in a subgroup
they called ‘‘mixed FLHCC’’ (19).
The aim of this study was to describe the clinical, surgical,
and histopathological features from a series of 21 cases of
fibrolamellar hepatocellular carcinoma, with an emphasis
on prognostic factors for survival.
& MATERIALS AND METHODS
Medical records from 21 patients with histopathologically
diagnosed FLHCC from 1990 to 2012 were reviewed and
searched for patient demographics, medical histories, the
results of imaging studies, laboratory tests, surgical proce-
dures, and outcomes. An experienced liver pathologist
(VAFA) reviewed all biopsies and surgical specimens.
Patients were staged according to the 7th edition of the
American Joint Committee on Cancer (AJCC) staging
criteria (20). The study was approved by the Hospital das
Clı´nicas from the University of Sa˜o Paulo School of
Medicine Ethics Committee and was conducted in accor-
dance with the Declaration of Helsinki.
The pathological diagnosis of FLHCC was based on the
presence of the following criteria: 1) large tumor cells with
deeply eosinophilic cytoplasm; 2) the presence of central
macronucleoli; and 3) abundant, fibrous stroma arranged in
thin, parallel lamellae around the tumor cells (4).
Similarly to the proposal by Malouf et al. (19), the cases
were divided into two groups: pure FLHCC, in which the
diagnostic criteria described above were present throughout
all samples available from the tumor, and mixed FLHCC, in
which at least one focus of conventional HCC was found in
a tumor with extensive areas of typical FLHCC. The
presence of micro- or macrovascular invasion, satellite
nodules, and extra-hepatic disease was also evaluated.
Immunohistochemical staining for the markers Hep-Par,
Arginase-1, Muc-1, CK19, CK7, and chromogranin was
performed in all specimens. To avoid endogenous avidin-
biotin interactions, which might yield undesirable back-
ground staining, signal amplification was achieved by the
use of a short-polymer peroxidase complex (Novolink,
Novocastra, U.K.). The immunoprofile was used to confirm
the diagnosis: classical FLHCC was expected to be positive
for Hep-Par, Arginase-1, and CK-7 and to present only focal
staining for Muc-1 and CK19, whereas the neuroendocrine
marker chromogranin was expected to be negative.
Overall survival (OS) was defined as the interval between
the diagnosis and the last follow up or death from any cause. A
survival analysis was conducted using the Kaplan-Meier
method (21) and compared by simple and multiple Cox
Regression analyses using R version 2.15.2. Differences were
considered significant at p , 0.05. Whenever it was not
possible to use the Cox regression, differences were evaluated
by the Log-Rank test using R version 2.15.2 (R Core Team, R
Foundation for Statistical Computing, Vienna, Austria, 2011)
(22). We analyzed the impact of the following factors on OS:
treatment (surgical vs. nonsurgical), AJCC staging (I/II vs. III/
IV), recurrence, and radiological and pathological features
(macro- and microvascular invasion, extra-hepatic disease,
and pathologic classification - pure FLHCC vs. mixed FLHCC).
& RESULTS
The clinicopathologic features and tumor staging, based
on imaging studies and histopathological examination, of 21
patients with FLHCC are summarized in Table 1.
The diagnosis was made by percutaneous biopsy in 62%
of cases and by surgical biopsy or surgical specimen
examination in 38%. The histological review confirmed the
diagnosis of FLHCC in all 21 specimens. Using the
proposed sub-classification by Malouf et al., 18 patients
had ‘‘pure FLHCC,’’ whereas three patients (14%) had at
least one distinct area of conventional HCC and were thus
classified as having ‘‘mixed FLHCC’’. Macrovascular inva-
sion was analyzed according to radiological and pathologi-
cal findings. Additionally, histological assessment was
performed to search for microvascular invasion.
None of the patients had tumor-associated chronic liver
disease or cirrhosis or a history of hepatic adenoma, and the
Table 1 - Clinicopathological features of 21 patients with
fibrolamellar hepatocellular carcinoma.
Characteristics All patients
Age (years, median, range) 20 (13 – 49)
Gender (male/female, %) 33/67
Tumor staging (TNM, n, %)
I or II 6 (28%)
III or IV 15 (72%)
Tumor size (cm, median, range) 12 (6 – 19)
Tumor size.10 cm (n, %)* 13 (68%)
Vascular invasion (n, %)* 8 (42%)
Microvascular invasion 3 (16%)
Macrovascular invasion 5 (26%)
Extra-hepatic metastasis (n, %) 13 (62%)
Treatment (n, %)
Surgery 9 (43%)
Surgery + systemic therapy 5 (24%)
QT Chemotherapy 3 (14%)
Palliative care 4 (19%)
Recurrence (n, %)** 8 (80%)
Site of recurrence (n, %)
Liver 3 (38%)
Lymph node 3 (38%)
Liver and lymph node 1 (12%)
Peritoneal implants 1 (12%)
Histology (n, %)
Pure fibrolamellar hepatocellular carcinoma 18 (86%)
Mixed fibrolamellar hepatocellular carcinoma 3 (14%)
*Tumor size and vascular invasion were evaluated in 19 patients;
** Recurrence was evaluated in 10 patients.
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AFP level was normal in all patients at diagnosis. Two
patients had portal hypertension associated with portal vein
thrombosis. All patients had symptoms at the time of
presentation, and the most common symptoms were
abdominal pain (65%), weight loss (60%), abdominal mass
(50%) and nausea (35%). Two patients in our series had been
pregnant but had delivered shortly before tumor diagnosis.
Using imaging studies, tumor staging was evaluated in 20
patients (Figure 1). In radiological studies at diagnosis, most
patients had a single nodule (90%), and the median tumor
size was 120 mm (6.6-19 cm). Vascular invasion was present
in 30% of patients, and extra-hepatic metastases were
present in 53%; all cases with extra-hepatic metastases
involved metastasis to regional lymph nodes. One patient
had also an image suggestive of lung metastasis, whereas 3
patients had mediastinal lymph node metastases.
Twenty patients underwent surgery. In six cases, the
tumor was considered unresectable, due either to extensive
liver involvement or to the presence of extra-hepatic
disease. Of these, four patients received palliative care,
and two received chemotherapy. One patient who did not
undergo surgery due to the presence of supraclavicular
lymph node metastasis. Fourteen patients underwent
resection as the first-line therapy. Nine patients (43%)
underwent only surgical resection. Five patients (24%)
received surgery plus chemotherapy.
Pathological staging was studied in 13 patients who
underwent resection (Figure 2). The median tumor size was
12 cm (6-19 cm) in the surgical specimens. Vascular inva-
sion was present in 5/13 (38%) patients, microvascular
invasion was present in 3 patients, and macrovascular
invasion was present in 2 patients. One patient had satellite
nodules. Extra-hepatic metastases were observed in 6/13
(46%) patients, and the most common sites of metastasis
were intra-abdominal lymph nodes (5/6, 83%). A positive
surgical margin was present in 5/13 (38%) patients.
Recurrence after resection was evaluated in 10 patients;
eight of them presented FLHCC recurrence. The median
time from resection to recurrence was 12 months
(Figure 3A). The most common sites of recurrence were
the liver (3/8) and abdominal lymph nodes (3/8). One
patient had recurrence in both the liver and lymph nodes,
and one had peritoneal implants. Two patients underwent
surgery for liver recurrences, and both evolved new
recurrences. One of them underwent another resection; this
patient has now been living disease free for 20 years. The
other patient had peritoneal mass recurrence, which
evolved to progressive disease and death. Three patients
with recurrences received chemotherapy, and the other
three received palliative care. As depicted in Figure 3A, the
presence of either macro- or microvascular invasion on
anatomopathological examination was found to be signifi-
cantly related to an increased risk of recurrence (p = 0.01).
All patients without recurrence were still alive at the end of
the study.
The tumor staging of the 21 patients using the TNM
system, according to radiological and pathological findings,
was as follows: stage I (TNM) in 5 patients, stage II in one,
stage III in three patients and stage IV in 12 patients (60%)
(Table 1).
Nineteen patients were followed, with a mean follow-up
of 24 months. Fourteen patients died; five patients are still
alive, three of whom are disease-free. Two patients are
being treated with chemotherapy and are experiencing
progressive disease. The median overall survival of the
entire series was 36 months (6-228 months). The presence of
macrovascular invasion, according to radiological and
pathological findings (Figure 3B), and the presence of areas
of conventional HCC in ‘‘mixed FLHCC’’ (Figure 4) were
associated with a worse survival, as assessed by the Log-
Rank test.
In the univariate and multivariate analyses, the presence
of ‘‘mixed FLHCC’’ was a predictor of poor survival
(p = 0.04). Patients who underwent surgery had a better
Figure 1 - Abdominal computerized tomography of a patient
with fibrolamellar hepatocellular carcinoma. (A) Contrast-
enhanced, arterial-phase computed tomography showing het-
erogeneous enhancement of a large solid mass with small
necrotic foci in segments IV and V of the liver. (B) Contrast-
enhanced, arterial-phase computed tomography showing an
enlarged lymph node in the hepatic portal (arrow).
Figure 2 - Pathological aspects of fibrolamellar hepatocellular
carcinoma. (A) Surgical specimen of a large, well-circumscribed,
yellow, heterogeneous mass with areas of necrosis and a central
scar. (B) Histopathology of ‘‘pure fibrolamellar hepatocellular
carcinoma’’: large tumor cells with deeply eosinophilic cyto-
plasm, round, central macronucleoli, and abundant fibrous
stroma arranged in thin parallel lamellae around the tumor
cells. (C): Fibrolamellar hepatocellular carcinoma showing micro-
vascular invasion; (D): ‘‘Mixed fibrolamellar hepatocellular
carcinoma’’: classical fibrolamellar hepatocellular carcinoma cells
are found intermingled with neoplastic cells with features of
conventional hepatocellular carcinoma.
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one-year survival rate (87.5%) compared with those who
underwent chemotherapy, surgery plus chemotherapy, and
palliative care (66%, 60%, and 50%, respectively, p = 0.05)
(Figure 5).
& DISCUSSION
FLHCC is an infrequent primary liver tumor presenting
significant epidemiological and clinical differences compared
with conventional hepatocellular carcinoma. Although the
real incidence and clinicopathological features of FLHCC in
Latin America remain poorly understood due to scarce
available information (6-8), the present study of 21 cases from
Figure 4 - The overall survival of patients with fibrolamellar
hepatocellular carcinoma according to the presence of areas of
conventional hepatocellular carcinoma (mixed hepatocellular
carcinoma vs. pure fibrolamellar hepatocellular carcinoma).
Figure 5 - The overall survival of patients with fibrolamellar
hepatocellular carcinoma according to treatment.
Figure 3 - (A) Overall disease-free survival of resected patients with fibrolamellar hepatocellular carcinoma according to vascular
invasion. Vascular invasion, either macro- or microscopic, was associated with an increased risk of tumor recurrence (Cox regression,
p,0.01). (B) The overall survival of patients with fibrolamellar hepatocellular carcinoma according to the presence of vascular invasion.
On the one hand, the presence of macrovascular invasion had a significant impact on survival; on the other hand, although the
microvascular invasion data may suggest a trend, the small number of cases (3) did not allow for a significant discrimination with cases
without any vascular invasion.
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a single tertiary hospital suggests either that the incidence of
cases at this particular hospital might be increased due to
increased referrals or that FLHCC may be less rare than
expected. In our series, as observed in other studies, FLHCC
occurred in young patients with a median age of 20 years
and without associated chronic liver disease (11-23). Most
patients in our study were female (14/21, 67%), similarly to
some other studies (8,11); however, other series did not show
a gender predilection for FLHCC (9,10,23). Two patients in
our series had been pregnant shortly before tumor diagnosis.
Some cases of FLHCC have been reported during pregnancy
(24,25), and some studies have associated FLHCC with the
use of oral contraceptives (4,8). The influence of hormonal
stimulation in the development of FLHCC remains unclear.
Thus, future studies should address the hypothesis raised
herein that estrogens might play a role in the pathophysiol-
ogy of this tumor.
The data described in the present series highlight relevant
epidemiological differences between FLHCC and conven-
tional HCC. In contrast with our study on FLHCC, a
multicenter Brazilian study conducted by Carrilho et al.
reported that 1,405 patients who were diagnosed with
conventional HCC had a median age at diagnosis of 59
years old and were mostly male (78%); additionally, the vast
majority of these patients (98%) had liver cirrhosis (27).
More clinical and epidemiological differences between
FLHCC and HCC have been described previously (10,12).
In the present study, all patients were symptomatic at
diagnosis, and the most common symptoms were abdom-
inal pain, weight loss, and nausea, as described in other
series (6,8,23), which likely reflects an advanced stage of
disease at diagnosis (60% had a pTNM stage IV). Most
patients presented a large hepatic mass; the median tumor
size was 12 cm. More than half of the patients presented
with extra-hepatic disease, including remarkable lymph
node involvement. Vascular invasion was also present in
42% of the patients, as evaluated by radiological and
pathological findings.
Among the 20 patients who underwent surgery, six
tumors were considered unresectable due either to exten-
sive liver involvement or to the presence of unresectable
extra-hepatic disease. This was similar to the 13 unresect-
able cases found by Stipa et al. (12) in a series of 41 patients
with FLHCC. Out of the 13 patients resected in our series
with pathological staging, the median tumor size was
12 cm, 38% had vascular invasion, and 46% had lymph
node metastases. Maniaci et al. (23), reported a series of 10
FLHCC cases with a mean tumor diameter of 13.4 cm, and
7/10 resected patients had lymph node metastases. In
another series reported by Pinna et al. (28), 41 patients with
FLHCC underwent surgical treatment; these cases had a
median tumor size of 13 cm, microvascular invasion
(51.2%), and macrovascular invasion (24.4%); 90% were
pTNM stage IV.
Diagnosis at an advanced stage of disease may be related
to the fact that FLHCC occurs in young patients without
chronic liver disease who are thus not subjected to a
screening program. In our institution, cirrhotic patients are
evaluated through an HCC screening program, which
allows for diagnosis in the early and asymptomatic stages
of disease (26). In a Brazilian multicenter study, most
patients were asymptomatic, and the majority of conven-
tional HCC cases were diagnosed in the early or inter-
mediate stage (27).
Although FLHCC is commonly diagnosed in the
advanced stage, resection remains the best option to achieve
disease control (23,28,29). In our series, 17/21 (81%) patients
were treated. Fourteen patients underwent surgery as the
first-line therapy, and liver resection was associated with
lymphadenectomy in six. Nine patients (43%) underwent
only resection, and five also received adjuvant chemother-
apy. The other three patients (14%) received chemotherapy
alone. In the present study, patients who underwent
surgical treatment alone showed a strong tendency towards
a better survival when compared with those who under-
went other forms of treatment, such as chemotherapy,
surgery plus chemotherapy, or palliative care (p = 0.05). This
finding is likely related to an early tumor stage at diagnosis,
allowing these patients to undergo surgery without adju-
vant chemotherapy. Other studies also reported a better
survival in patients who underwent surgical treatment
compared with unresectable patients (8,11,12).
The follow-up of the 10 patients who were surgically
treated showed tumor recurrence in eight cases. The median
time to recurrence was 12 months, and vascular invasion
was associated with an increased risk of tumor recurrence.
Previous studies have also reported a high recurrence rate,
ranging from 36 - 100%, with a median time to relapse
between 10 and 33 months (11,28,29). In a series of 28
patients who underwent resection, Stipa et al. (12) reported
that the five-year recurrence-free survival rate was 18%, and
the only significant negative prognostic factor for recurrence
was the presence of lymph node metastases. Pinna et al. (28)
reported that the pTNM stage was significantly associated
with tumor-free survival. All patients without tumor
recurrence were still alive at the end of our study,
suggesting that postsurgical tumor recurrence is likely a
major prognostic factor in patients with FLHCC.
In contrast to adenocarcinomas from almost all other
organs, for which the identification of histological subtypes
has led to the search for specific molecular profiles and, in
many instances, to the classification of entirely different
clinical-pathological entities, most studies report ‘‘hepato-
cellular carcinoma’’ as a generic tumor type, and thus do not
acknowledge the potential for different origins and biologi-
cal behaviors. In this regard, Malouf et al. (30) have recently
reported the relevance of the identification of stromal-rich
HCCs, which are subtyped with poor reproducibility even
among experts. This fact could at least partially explain the
under-reporting of FLHCC even in regions such as Latin
America where it does not appear to be so rare. Indeed, this
is one of the major motivations for the present report, with
an emphasis on updating the clinical and histopathological
criteria for the definition of FLHCC as an important subtype
of HCC. In the present series, pure FLHCC was associated
with a significantly higher overall survival, whereas mixed
FLHCC was associated with an increased risk of death. This
finding is consistent with recent data from Malouf et al.,
who reported a longer median overall survival in patients
with pure FLHCC compared with patients with mixed
FLHCC (9 years vs. 3 years; p,0.02) (19). Mixed FLHCC
was reported for 10% to 25% of tumors in some series
(12,19).
Other factors that were associated with a worse prognosis
in other studies include vascular invasion, lymph node
metastasis, positive surgical margins, and old age (4,12). In
our study, the presence of macrovascular invasion, accord-
ing to radiological and pathological findings, was associated
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with poor survival. The presence of microvascular invasion,
however, was not shown to be associated with worse
survival; this is likely because only 3 cases presented
microvascular invasion. Pinna et al. (28) reported vascular
invasion as the most important negative prognostic factor
for survival in their series. Lymph node metastasis was the
only significant negative prognostic factor in the series
reported by Stipa et al. (12). In a series of 15 patients with
FLHCC, Moreno-Luna reported that the factors associated
with higher survival were age over 23 years, resectability,
the absence of major vascular invasion, and free surgical
borders (8). In our series, other poor prognostic factors, such
as extra-hepatic metastasis and positive margins, were
associated with worse survival, but these associations were
not statistically significant, likely because of the small
number of patients.
An important finding from morphological studies is the
growing necessity for extensive histological sampling to
search for tumor heterogeneity because the presence of
areas of conventional HCC in FLHCC was related to poor
survival. Our recommendation is that in addition to the
selection of all areas presenting gross features of possible
markers of worse prognosis, such as intra-hepatic satellite
nodules, vascular invasion, and extra-hepatic invasion,
including lymph node and organ metastases, at least one
paraffin block should be prepared for each centimeter of the
largest extension of the primary tumor.
The results from the multivariate analysis should be
interpreted with caution because the small sample size and
small number of events by covariate analysis can introduce
estimation bias for the hazard ratios (31). However, as
FLHCC is considered a rare type of cancer, the number of
cases presented herein is among the largest published series
from a single institution.
In conclusion, in the present series of 21 cases from a
single academic center, fibrolamellar hepatocellular carci-
noma was more common in young female patients, none of
whom had evidence of chronic liver disease. The majority of
patients were diagnosed at an advanced stage and had large
tumors; additionally, most already had extra-hepatic metas-
tases, especially to lymph nodes. Whenever feasible, surgery
is the best therapeutic option to achieve disease control,
even in advanced cases. Vascular invasion was related to a
significantly higher risk of recurrence in patients who
underwent surgical resection, and the presence of macro-
vascular invasion in imaging or pathology studies was a
predictor of poor survival. Our findings suggest that
extensive histological sampling must be performed to
search for tumor heterogeneity because the presence of
areas of conventional HCC in FLHCC was directly related to
poor survival.
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